市場調查報告書

酸性神經磷脂酶缺損症(ASMD)- 流行病學預測 2028年

Acid sphingomyelinase deficiency (ASMD) - Epidemiology Forecast to 2028

出版商 DelveInsight Business Research LLP 商品編碼 911515
出版日期 內容資訊 英文 60 Pages
商品交期: 最快1-2個工作天內
價格
酸性神經磷脂酶缺損症(ASMD)- 流行病學預測 2028年 Acid sphingomyelinase deficiency (ASMD) - Epidemiology Forecast to 2028
出版日期: 2019年09月01日內容資訊: 英文 60 Pages
簡介

新興10個國家(土耳其、俄羅斯、沙烏地阿拉伯、阿拉伯聯合大公國、墨西哥、哥倫比亞、巴西、阿根廷、中國、台灣)的2017年的酸性神經磷脂酶缺損症(ASMD)的患病人數估算為8,799人。

本報告提供新興10個國家(土耳其、俄羅斯、沙烏地阿拉伯、阿拉伯聯合大公國、墨西哥、哥倫比亞、巴西、阿根廷、中國、台灣)的酸性神經磷脂酶缺損症(ASMD)的流行病學的相關調查,疾病概要,各表現型、臨床症狀、各國流行病學的預測,以整體及各國的患病數及診斷數量詳細彙整。

目錄

第1章 重要洞察

第2章 酸性神經磷脂酶缺損症(ASMD)概要

  • 分佈情形(成果值)
  • 分佈情形(預測值)

第3章 疾病背景和概要

  • 簡介
  • 歷史
  • 各病型
    • NPD-A(尼曼匹克症 A型)
    • NPD-B(尼曼匹克症 B型)
  • 病因
  • 症狀
  • 病理生理學
  • 診斷
  • 生物標記

第4章 流行病學和患者人口:各地區

  • 主要調查結果
  • 關鍵意見領袖的意見

第5章 新興10個國家的酸性神經磷脂酶缺損症(ASMD)的總罹患數

  • 總患病數
  • 診斷患病數

第6章 酸性神經磷脂酶缺損症(ASMD)的各國流行病學

  • 假設和理論的根據
  • 中國
    • 總患病數
    • 診斷數量
    • 診斷數量:各表現型
    • 診斷數量:各臨床症狀
  • 台灣
    • 總患病數
    • 診斷數量
    • 診斷數量:各表現型
    • 診斷數量:各臨床症狀
  • 沙烏地阿拉伯
    • 總患病數
    • 診斷數量
    • 診斷數量:各表現型
    • 診斷數量:各臨床症狀
  • 阿拉伯聯合大公國
    • 總患病數
    • 診斷數量
    • 診斷數量:各表現型
    • 診斷數量:各臨床症狀
  • 俄羅斯
    • 總患病數
    • 診斷數量
    • 診斷數量:各表現型
    • 診斷數量:各臨床症狀
  • 土耳其
    • 總患病數
    • 診斷數量
    • 診斷數量:各表現型
    • 診斷數量:各臨床症狀
  • 墨西哥
    • 總患病數
    • 診斷數量
    • 診斷數量:各表現型
    • 診斷數量:各臨床症狀
  • 巴西
    • 總患病數
    • 診斷數量
    • 診斷數量:各表現型
    • 診斷數量:各臨床症狀
  • 阿根廷
    • 總患病數
    • 診斷數量
    • 診斷數量:各表現型
    • 診斷數量:各臨床症狀
  • 哥倫比亞
    • 總患病數
    • 診斷數量
    • 診斷數量:各表現型
    • 診斷數量:各臨床症狀

第7章 附錄

  • 調查手法

第8章 DelveInsight的服務內容

第9章 免責聲明

第10章 關於DelveInsight

目錄
Product Code: DIEI0379

DelveInsight's 'Acid sphingomyelinase deficiency (ASMD) - Epidemiology Forecast to 2028' report delivers an in-depth understanding of the disease, historical & forecasted epidemiology of Acid sphingomyelinase deficiency in the 10 Emerging Markets (EM) ,i.e., Turkey, Russia, Saudi Arabia, UAE, Mexico, Colombia, Brazil, Argentina, China and Taiwan.

Geography Covered

  • Asia (China and Taiwan)
  • Middle East (Turkey, Saudi Arabia, UAE)
  • Eastern Europe (Russia)
  • LATAM (Brazil, Mexico, Colombia and Argentina)

Study Period: 2017-2028

Acid sphingomyelinase deficiency Disease Understanding

Acid sphingomyelinase deficiency (ASMD) is a rare progressive genetic disorder that results from a deficiency of the enzyme acid sphingomyelinase, which is required to break down (metabolize) a fatty substance (lipid) called sphingomyelin and inherited in an autosomal recessive pattern. Acid sphingomyelinase, E.C. 3.1.4.12, (ASM) is a lysosomal phosphodiesterase enzyme that hydrolyzes sphingomyelin, a phospholipid storage substance found in the brain, liver, lungs, spleen and lymph nodes, to ceramide and phosphorylcholine. It is also known as Niemann-Pick disease.

Acid sphingomyelinase deficiency Epidemiology

The Acid sphingomyelinase deficiency (ASMD) epidemiology division provide the insights about historical and current patient pool and forecasted trend for every 10 emerging countries. The epidemiology data for Acid sphingomyelinase deficiency are studied through all possible division to give a better understanding about the Disease scenario in 10EM. It also helps to recognize the causes of current and forecasted trends by exploring numerous studies, survey reports and views of key opinion leaders.

Acid sphingomyelinase deficiency Epidemiology Segmentation

The disease epidemiology covered in the report provides historical as well as forecasted epidemiology (total prevalent population, total diagnosed cases of Acid sphingomyelinase deficiency, diagnosed cases of ASMD by clinical phenotype, and diagnosed cases of ASMD based on clinical manifestations) scenario of Acid sphingomyelinase deficiency (ASMD) in the 10EM covering Turkey, Russia, Saudi Arabia, UAE, Mexico, Colombia, Brazil, Argentina, China and Taiwan) from 2017-2028.

The DelveInsight report also provides the epidemiology trends observed in the 10EM during the study period, along with the assumptions undertaken. The calculated data are presented with relevant tables and graphs to give a clear view of the epidemiology at first sight.

According to DelveInsight, the total number of prevalent cases of Acid sphingomyelinase deficiency (ASMD) in 10EM was found to be 8,799, in the year 2017.

Report Scope

  • The report covers detailed overview of Acid sphingomyelinase deficiency explaining its causes, symptoms, classification, pathophysiology, diagnosis and treatment patterns
  • The report provides the insight about the historical and forecasted patient pool of Acid sphingomyelinase deficiency in 10 emerging markets covering Turkey, Russia, Saudi Arabia, UAE, Mexico, Colombia, Brazil, Argentina, China and Taiwan. The Report assesses the disease risk and burden and highlights the unmet needs of the disease
  • The Report helps to recognize the growth opportunities in the 10EM with respect to the patient population
  • The report provides the segmentation of the disease epidemiology by total prevalent population, total diagnosed cases of Acid sphingomyelinase deficiency, diagnosed cases of ASMD by clinical phenotype, and diagnosed cases of ASMD based on clinical manifestations in 10EM

Key strengths

  • 10 Year Forecast of Acid sphingomyelinase deficiency epidemiology
  • 10EM Coverage
  • Total Prevalent Cases of ASMDs
  • Prevalent Cases according to segmentation: total prevalent population, total diagnosed cases of Acid sphingomyelinase deficiency, diagnosed cases of ASMD by clinical phenotype, and diagnosed cases of ASMD based on clinical manifestations

Key assessments

  • Patient Segmentation
  • Disease Risk & Burden
  • Risk of disease by the segmentation
  • Factors driving growth in a specific patient population

Table of Contents

1. Key Insights

2. Acid sphingomyelinase deficiency Market Overview at a Glance

  • 2.1. Market Share (%) Distribution of Acid sphingomyelinase deficiency in 2017
  • 2.2. Market Share (%) Distribution of Acid sphingomyelinase deficiency in 2028

3. Disease Background and Overview

  • 3.1. Introduction
  • 3.2. History
  • 3.3. Sub-types
    • 3.3.1. NPD-A
    • 3.3.2. NPD-B
  • 3.4. Etiology of ASMD
  • 3.5. Sign and Symptoms
  • 3.6. Pathophysiology of ASMD
  • 3.7. Diagnosis
    • 3.7.1. Based on Chronic Visceral and Non-visceral ASMD
    • 3.7.2. Based on Other Diseases
  • 3.8. Biomarkers

4. Epidemiology and Patient Population - By Region

  • 4.1. Key Findings
  • 4.2. KOL Views

5. Ten Emerging Markets (EM) Total Prevalent Patient Population of Acid sphingomyelinase deficiency (ASMD)

  • 5.1. Total Prevalence of Acid sphingomyelinase deficiency in 10 Emerging Markets
  • 5.2. Diagnosed Prevalence of Acid sphingomyelinase deficiency in 10 Emerging Markets

6. Country Wise-Epidemiology of Acid sphingomyelinase deficiency (ASMD)

  • 6.1. Emerging Markets: Assumptions and Rationale
  • 6.2. China
    • 6.2.1. Total Prevalent Cases of ASMD in China
    • 6.2.2. Diagnosed Cases of ASMD in China
    • 6.2.3. Diagnosed Cases of ASMD by clinical phenotype in China
    • 6.2.4. Diagnosed Cases of ASMD based on clinical manifestations in China
  • 6.3. Taiwan
    • 6.3.1. Total Prevalent Cases of ASMD in Taiwan
    • 6.3.2. Diagnosed Cases of ASMD in Taiwan
    • 6.3.3. Diagnosed Cases of ASMD by clinical phenotype in Taiwan
    • 6.3.4. Diagnosed Cases of ASMD based on clinical manifestations in Taiwan
  • 6.4. Saudi Arabia
    • 6.4.1. Total Prevalent Cases of ASMD in Saudi Arabia
    • 6.4.2. Diagnosed Cases of ASMD in Saudi Arabia
    • 6.4.3. Diagnosed Cases of ASMD by clinical phenotype in Saudi Arabia
    • 6.4.4. Diagnosed Cases of ASMD based on clinical manifestations in Saudi Arabia
  • 6.5. U.A.E.
    • 6.5.1. Total Prevalent Cases of ASMD in UAE
    • 6.5.2. Diagnosed Cases of ASMD in UAE
    • 6.5.3. Diagnosed Cases of ASMD by clinical phenotype in UAE
    • 6.5.4. Diagnosed Cases of ASMD based on clinical manifestations in UAE
  • 6.6. Russia
    • 6.6.1. Total Prevalent Cases of ASMD in Russia
    • 6.6.2. Diagnosed Cases of ASMD in Russia
    • 6.6.3. Diagnosed Cases of ASMD by clinical phenotype in Russia
    • 6.6.4. Diagnosed Cases of ASMD based on clinical manifestations in Russia
  • 6.7. Turkey
    • 6.7.1. Total Prevalent Cases of ASMD in Turkey
    • 6.7.2. Diagnosed Cases of ASMD in Turkey
    • 6.7.3. Diagnosed Cases of ASMD by clinical phenotype in Turkey
    • 6.7.4. Diagnosed Cases of ASMD based on clinical manifestations in Turkey
  • 6.8. Mexico
    • 6.8.1. Total Prevalent Cases of ASMD in Mexico
    • 6.8.2. Diagnosed Cases of ASMD in Mexico
    • 6.8.3. Diagnosed Cases of ASMD by clinical phenotype in Mexico
    • 6.8.4. Diagnosed Cases of ASMD based on clinical manifestations in Mexico
  • 6.9. Brazil
    • 6.9.1. Total Prevalent Cases of ASMD in Brazil
    • 6.9.2. Diagnosed Cases of ASMD in Brazil
    • 6.9.3. Diagnosed Cases of ASMD by clinical phenotype in Brazil
    • 6.9.4. Diagnosed Cases of ASMD based on clinical manifestations in Brazil
  • 6.10. Argentina
    • 6.10.1. Total Prevalent Cases of ASMD in Argentina
    • 6.10.2. Diagnosed Cases of ASMD in Argentina
    • 6.10.3. Diagnosed Cases of ASMD by clinical phenotype in Argentina
    • 6.10.4. Diagnosed Cases of ASMD based on clinical manifestations in Argentina
  • 6.11. Colombia
  • 6.12. Total Prevalent Cases of ASMD in Colombia
  • 6.13. Diagnosed Cases of ASMD in Colombia
  • 6.14. Diagnosed Cases of ASMD by clinical phenotype in Colombia
  • 6.15. Diagnosed Cases of ASMD based on clinical manifestations in Colombia

7. Appendix

  • 7.1. Report Methodology

8. DelveInsight Capabilities

9. Disclaimer

10. About DelveInsight

List of Tables

  • Table 1: Characteristics of ASMD Subtypes
  • Table 2: Sign and Symptoms of ASMD
  • Table 3: Total Prevalence of Acid sphingomyelinase deficiency in 10 Emerging Markets (2017-2028)
  • Table 4: Diagnosed Prevalence of Acid sphingomyelinase deficiency in 10 Emerging Markets (2017-2028)
  • Table 5: Total Prevalent Cases of ASMD in China (2017-2028)
  • Table 6: Diagnosed Cases of ASMD in China (2017-2028)
  • Table 7: Total Prevalent Cases of ASMD by clinical phenotype in China (2017-2028)
  • Table 8: Total Prevalent Cases of ASMD based on clinical manifestations in China (2017-2028)
  • Table 9: Total Prevalent Cases of ASMD in Taiwan (2017-2028)
  • Table 10: Diagnosed Cases of ASMD in Taiwan (2017-2028)
  • Table 11: Total Prevalent Cases of ASMD by clinical phenotype in Taiwan (2017-2028)
  • Table 12: Total Prevalent Cases of ASMD based on clinical manifestations in Taiwan (2017-2028)
  • Table 13: Total Prevalent Cases of ASMD in Saudi Arabia (2017-2028)
  • Table 14: Diagnosed Cases of ASMD in Saudi Arabia (2017-2028)
  • Table 15: Total Prevalent Cases of ASMD by clinical phenotype in Saudi Arabia (2017-2028)
  • Table 16: Total Prevalent Cases of ASMD based on clinical manifestations in Saudi Arabia (2017-2028)
  • Table 17: Total Prevalent Cases of ASMD in UAE (2017-2028)
  • Table 18: Diagnosed Cases of ASMD in UAE (2017-2028)
  • Table 19: Total Prevalent Cases of ASMD by clinical phenotype in UAE (2017-2028)
  • Table 20: Total Prevalent Cases of ASMD based on clinical manifestations in UAE (2017-2028)
  • Table 21: Total Prevalent Cases of ASMD in Russia (2017-2028)
  • Table 22: Diagnosed Cases of ASMD in Russia (2017-2028)
  • Table 23: Total Prevalent Cases of ASMD by clinical phenotype in Russia (2017-2028)
  • Table 24: Total Prevalent Cases of ASMD based on clinical manifestations in Russia (2017-2028)
  • Table 25: Total Prevalent Cases of ASMD in Turkey (2017-2028)
  • Table 26: Diagnosed Cases of ASMD in Turkey (2017-2028)
  • Table 27: Total Prevalent Cases of ASMD by clinical phenotype in Turkey (2017-2028)
  • Table 28: Total Prevalent Cases of ASMD based on clinical manifestations in Turkey (2017-2028)
  • Table 29: Total Prevalent Cases of ASMD in Mexico (2017-2028)
  • Table 30: Diagnosed Cases of ASMD in Mexico (2017-2028)
  • Table 31: Total Prevalent Cases of ASMD by clinical phenotype in Mexico (2017-2028)
  • Table 32: Total Prevalent Cases of ASMD based on clinical manifestations in Mexico (2017-2028)
  • Table 33: Total Prevalent Cases of ASMD in Brazil (2017-2028)
  • Table 34: Diagnosed Cases of ASMD in Brazil (2017-2028)
  • Table 35: Total Prevalent Cases of ASMD by clinical phenotype in Brazil (2017-2028)
  • Table 36: Total Prevalent Cases of ASMD based on clinical manifestations in Brazil (2017-2028)
  • Table 37: Total Prevalent Cases of ASMD in Argentina (2017-2028)
  • Table 38: Diagnosed Cases of ASMD in Argentina (2017-2028)
  • Table 39: Total Prevalent Cases of ASMD by clinical phenotype in Argentina (2017-2028)
  • Table 40: Total Prevalent Cases of ASMD based on clinical manifestations in Argentina (2017-2028)
  • Table 41: Total Prevalent Cases of ASMD in Colombia (2017-2028)
  • Table 42: Diagnosed Cases of ASMD in Colombia (2017-2028)
  • Table 43: Total Prevalent Cases of ASMD by clinical phenotype in Colombia (2017-2028)
  • Table 44: Total Prevalent Cases of ASMD based on clinical manifestations in Colombia (2017-2028)

List of Figures

  • Figure 1: The SMPD1 gene on Chromosome 11
  • Figure 2: The autosomal recessive inheritance of ASMD
  • Figure 3: Symptoms of Acid Sphingomyelinase Deficiency.
  • Figure 4: Clinical Manifestations of NPD-B By Organ Class
  • Figure 5: The Metabolic pathway of Niemann-Pick type-A and type-B
  • Figure 6: The Diagnostic Algorithm of ASMD
  • Figure 7: Total Prevalence of Acid sphingomyelinase deficiency in 10 Emerging Markets (2017-2028)
  • Figure 8: Diagnosed Prevalence of Acid sphingomyelinase deficiency in 10 Emerging Markets (2017-2028)
  • Figure 9: Total Prevalent Cases of ASMD in China (2017-2028)
  • Figure 10: Diagnosed Cases of ASMD in China (2017-2028)
  • Figure 11: Total Prevalent Cases of ASMD by clinical phenotype in China (2017-2028)
  • Figure 12: Total Prevalent Cases of ASMD based on clinical manifestations in China (2017-2028)
  • Figure 13: Total Prevalent Cases of ASMD in Taiwan (2017-2028)
  • Figure 14: Diagnosed Cases of ASMD in Taiwan (2017-2028)
  • Figure 15: Total Prevalent Cases of ASMD by clinical phenotype in Taiwan (2017-2028)
  • Figure 16: Total Prevalent Cases of ASMD based on clinical manifestations in Taiwan (2017-2028)
  • Figure 17: Total Prevalent Cases of ASMD in Saudi Arabia (2017-2028)
  • Figure 18: Diagnosed Cases of ASMD in Saudi Arabia (2017-2028)
  • Figure 19: Total Prevalent Cases of ASMD by clinical phenotype in Saudi Arabia (2017-2028)
  • Figure 20: Total Prevalent Cases of ASMD based on clinical manifestations in Saudi Arabia (2017-2028)
  • Figure 21: Total Prevalent Cases of ASMD in UAE (2017-2028)
  • Figure 22: Diagnosed Cases of ASMD in UAE (2017-2028)
  • Figure 23: Total Prevalent Cases of ASMD by clinical phenotype in UAE (2017-2028)
  • Figure 24: Total Prevalent Cases of ASMD based on clinical manifestations in UAE (2017-2028)
  • Figure 25: Total Prevalent Cases of ASMD in Russia (2017-2028)
  • Figure 26: Diagnosed Cases of ASMD in Russia (2017-2028)
  • Figure 27: Total Prevalent Cases of ASMD by clinical phenotype in Russia (2017-2028)
  • Figure 28: Total Prevalent Cases of ASMD based on clinical manifestations in Russia (2017-2028)
  • Figure 29: Total Prevalent Cases of ASMD in Turkey (2017-2028)
  • Figure 30: Diagnosed Cases of ASMD in Turkey (2017-2028)
  • Figure 31: Total Prevalent Cases of ASMD by clinical phenotype in Turkey (2017-2028)
  • Figure 32: Total Prevalent Cases of ASMD based on clinical manifestations in Turkey (2017-2028)
  • Figure 33: Total Prevalent Cases of ASMD in Mexico (2017-2028)
  • Figure 34: Diagnosed Cases of ASMD in Mexico (2017-2028)
  • Figure 35: Total Prevalent Cases of ASMD by clinical phenotype in Mexico (2017-2028)
  • Figure 36: Total Prevalent Cases of ASMD based on clinical manifestations in Mexico (2017-2028)
  • Figure 37: Total Prevalent Cases of ASMD in Brazil (2017-2028)
  • Figure 38: Diagnosed Cases of ASMD in Brazil (2017-2028)
  • Figure 39: Total Prevalent Cases of ASMD by clinical phenotype in Brazil (2017-2028)
  • Figure 40: Total Prevalent Cases of ASMD based on clinical manifestations in Brazil (2017-2028)
  • Figure 41: Total Prevalent Cases of ASMD in Argentina (2017-2028)
  • Figure 42: Diagnosed Cases of ASMD in Argentina (2017-2028)
  • Figure 43: Total Prevalent Cases of ASMD by clinical phenotype in Argentina (2017-2028)
  • Figure 44: Total Prevalent Cases of ASMD based on clinical manifestations in Argentina (2017-2028)
  • Figure 45: Total Prevalent Cases of ASMD in Colombia (2017-2028)
  • Figure 46: Diagnosed Cases of ASMD in Colombia (2017-2028)
  • Figure 47: Total Prevalent Cases of ASMD by clinical phenotype in Colombia (2017-2028)
  • Figure 48: Total Prevalent Cases of ASMD based on clinical manifestations in Colombia (2017-2028)